Dr. Pusztai Discusses DNA Abnormalities in Breast Cancer

September 9, 2015
Lajos Pusztai, MD, PhD

Lajos Pusztai, MD, PhD, Yale Cancer Center, discusses DNA abnormalities in breast cancer.

Pusztai says there are only three types of abnormalities that oncologists can pick up. The best examples of FDA-approved drugs for breast cancer are HER2-amplification and HER2-targeted therapies, such as trastuzumab.

Some abnormalities have also been successfully targeted in other diseases, such as EGFR mutations, which can be targeted with gefitinib in lung cancer.

A common and important question is whether or not the abnormalities in breast cancer confer the same degree of sensitivity to a targeted drug, as they do in other disease types, says Pusztai.

Lajos Pusztai, MD, PhD, professor of medicine (medical oncology), chief of Breast Medical Oncology, co-director, Cancer Genetics Research Program, Yale Cancer Center, discusses DNA abnormalities in breast cancer.